SEC Form 20-F filed by COSCIENS Biopharma Inc.
$CSCI
Biotechnology: Pharmaceutical Preparations
Health Care
Unavailable
Unavailable
Save time and jump to the most important pieces.
New Director Nominees are Strong Leaders to Revitalize COSCIENS TORONTO, May 23, 2025 /CNW/ - Goodwood Fund and Puccetti Funds Management Inc. (collectively, "Goodwood") announced today that Goodwood has notified COSCIENS Biopharma Inc. (NASDAQ:CSCI) (TSX:CSCI) that Goodwood intends to nominate six new highly qualified and experienced directors (the "Shareholder Nominees") for election at the upcoming annual and special meeting of COSCIENS' shareholders (the "Meeting") scheduled to be held on June 26, 2025. Goodwood beneficially owns, directly or indirectly, an aggregate of 257,257 common shares of COSCIENS, or approximately 8.2% of COSCIENS' outstanding common shares. On December 19, 2024,
Repositioned as a pure-play natural-based product company following strategic review and pipeline prioritization Efforts continue to gain efficiencies through streamlining and cost cutting measures; Company ended the quarter with US$13.8 million in cash Advancing Phase 2 clinical trial with Avenanthramide product Appoints Global Consumer Products and Biosciences Executive, Anna Biehn as Chief Executive Officer TORONTO, ONTARIO, May 13, 2025 (GLOBE NEWSWIRE) -- COSCIENS Biopharma Inc. (NASDAQ:CSCI) (TSX:CSCI) ("COSCIENS" or the "Company"), a life sciences company which develops and commercializes a diversified portfolio of cosmeceutical, nutraceutical and pharmaceutical products, today
25+ years of experience in executive leadership roles and developing global strategic growth plans with repeatable models applicable across markets, categories and channels Current President and CEO, Gilles Gagnon to remain as a Strategic Advisor and Director Company leveraging core competencies to develop and commercializenatural-based products to improve health and wellness TORONTO, ONTARIO, April 14, 2025 (GLOBE NEWSWIRE) -- COSCIENS Biopharma Inc. (NASDAQ:CSCI) (TSX:CSCI) ("COSCIENS" or the "Company"), a life science company which develops and commercializes a diversified portfolio of cosmeceutical, nutraceutical and pharmaceutical products, today announced the appointment of Anna B
6-K - COSCIENS Biopharma Inc. (0001113423) (Filer)
6-K - COSCIENS Biopharma Inc. (0001113423) (Filer)
6-K - COSCIENS Biopharma Inc. (0001113423) (Filer)
SC 13D - COSCIENS Biopharma Inc. (0001113423) (Subject)
Repositioned as a pure-play natural-based product company following strategic review and pipeline prioritization Efforts continue to gain efficiencies through streamlining and cost cutting measures; Company ended the quarter with US$13.8 million in cash Advancing Phase 2 clinical trial with Avenanthramide product Appoints Global Consumer Products and Biosciences Executive, Anna Biehn as Chief Executive Officer TORONTO, ONTARIO, May 13, 2025 (GLOBE NEWSWIRE) -- COSCIENS Biopharma Inc. (NASDAQ:CSCI) (TSX:CSCI) ("COSCIENS" or the "Company"), a life sciences company which develops and commercializes a diversified portfolio of cosmeceutical, nutraceutical and pharmaceutical products, today
25+ years of experience in executive leadership roles and developing global strategic growth plans with repeatable models applicable across markets, categories and channels Current President and CEO, Gilles Gagnon to remain as a Strategic Advisor and Director Company leveraging core competencies to develop and commercializenatural-based products to improve health and wellness TORONTO, ONTARIO, April 14, 2025 (GLOBE NEWSWIRE) -- COSCIENS Biopharma Inc. (NASDAQ:CSCI) (TSX:CSCI) ("COSCIENS" or the "Company"), a life science company which develops and commercializes a diversified portfolio of cosmeceutical, nutraceutical and pharmaceutical products, today announced the appointment of Anna B
TORONTO, ONTARIO, Oct. 01, 2024 (GLOBE NEWSWIRE) -- COSCIENS Biopharma Inc. (NASDAQ:CSCI) (TSX:CSCI) ("COSCIENS" or the "Company"), a specialty biopharmaceutical company developing and commercializing a diversified portfolio of cosmeceutical, nutraceutical and pharmaceutical products, announced the appointment of Pierre Labbé to its board of directors and as Chair of the Company's Audit Committee, effective today, to fill the vacancy created by the resignation of Dennis Turpin, also effective today. Mr. Labbé has more than 30 years of progressive financial leadership roles in various industries. Mr. Labbé is currently the Executive Vice-President, Finance of Fonds QScale S.E.C., which is